2-Respiratory Failure
2-Respiratory Failure
Its classification into types I and II is defined by the absence or presence of hypercapnia (raised
partial pressure
PaCO2 ).
Pathophysiology
( Alveoli )ھﻮاء واﺻﻞventilation اﻛﻮ ﺗﮭﻮﯾﺔ
( او ﻋﻜﺲAlveoli ) دم ﻣﺎ واﺻﻞperfusion و ﻣﺎﻛﻮ
)
ﺗﻨﻔﺲ/ ﺗﮭﻮﯾﺔ 2- ventilation/perfusion
1-
When disease impairs ventilation of part of a lung (e.g. in asthma or pneumonia), perfusion V/
دخول الدم املحمل بثاني أكسيد الكربون
3-
Q mismatch of that region results in hypoxic and CO2-laden blood entering the pulmonary
shunt :- atrial or ventricular septal
shunt ھﻮ ﻧﻔﺴﮭﺎPathophysiology ب٣ ﻧﻘﻄﺔ
veins. shunt و ﻧﻄﯿﮫ اوﻛﺴﺠﯿﻦ و ﻣﺎ ﯾﺘﺤﺴﻦ ف ﻋﻨﺪهhypoxia اذا ﻣﺮﯾﺾ
defect , patent ductus arteriosus ,
Increased ventilation of neighbouring regions of normal lung can increase CO2 excretion,
correcting arterial CO2 to normal,
اﺧﺘﻼط
Admixture of blood from the under-ventilated and normal regions thus results in hypoxia with
normocapnia, which is called ‘type I respiratory failure’.
Arterial hypoxia with hypercapnia (type II respiratory failure) is seen in conditions that cause
generalised, severe ventilation–perfusion mismatch, leaving insufficient normal lung to correct
PaCO2 , or any disease that reduces total ventilation in neuromuscular disorders.
Or due to shunt as in Pulmonary arteriovenous malformations (PAVMs) ArterioVenous
Malformations
ﺟﺪول ﻣﮭﻢ
ارﻗﺎم ﺣﻔﻆ
ارﻗﺎم ﺣﻔﻆ
ﺳﻜﻤﺎ
anaplasia
l s ﻣﺨﺪر ﺿﻌﻒ ﻋﻀﻼت ﺗﻨﻔﺲ
Oxygen should be administered to maintain the SaO2 within the target range of 94%–98% for
ف ﻣﺮاﻛﺰ ﺗﻨﻔﺲ ﺑﺪﻣﺎغ راح ﺗﮭﺪء و ﯾﺒﺪيhypoxia اذا ﻧﺤﺴﻦ
ﯾﺘﺮاﻛﻢ ﺑﺎﻟﺪم و ﯾﺼﯿﺮ دم ﺣﺎﻣﻀﻲ و ﺑﺘﺎﻟﻲ ﯾﻤﻮت ﻣﺮﯾﺾCO2
those with type l respiratory failure , or 88%–92% for those patients at risk of type II respiratory
failure, pending a rapid examination of the respiratory system and measurement of arterial
blood gases.
A small proportion of patients with severe chronic lung disease and type II respiratory failure
ﺗﺤﻤﻞ
develop abnormal tolerance to raised PaCO2 and may become dependent on hypoxic drive to
breathe. In these patients only, lower concentrations of oxygen (24%–28% by Venturi mask)
should be used to avoid precipitating worsening respiratory depression
1- 2- اﻧﺨﻔﺎض
Failure to respond to initial treatment, declining conscious level and worsening respiratory
3- 4- CPAP
acidosis (pH <7.35), PaCO2 >6.6 kPa) on blood gases are all indications that supported
ventilation is required. kPa 6.6 بابثاني أوكسيد كاربون اكثر-4 حامضي الدم-3 وعيه يقل-2 ما يستجيب للعالج-1 اذا مريض
سيCPAP و نشدله جهازICU ف راح نطبب مريض لالنعاش
The obstructive sleep apnoea/hypopnoea syndrome pnoea = breathing
وراثة
sleep-disordered breathing is
1-
associated over time with sustained
hypertension and an increased risk of
2- 3-
co ro n a r y events a n d stro ke.
Associations
4-
have also been 5-described
with insulin resistance, the metabolic
6-
syndrome and type 2 diabetes.
In addition to improving symptoms
and reducing vehicular risk,
treatment of sleep apnoea reduces
sympathetic drive and blood pressure
and may also improve these
associated metabolic disorders.
Clinical features
Excessive daytime sleepiness is the principal symptom and snoring
ًتقريبا عالي
is virtually universal.
The patient usually feels that he or she has been asleep all night
غير مدرك يتذكر اختناق
gasping episodes.
ﯾﻌﻨﻲ ﯾﻔﺘﺢ ﺷﺒﺎك و ﺑﺲ ﯾﺮﯾﺪ ھﻮء
تركيز ادراك
• Overweight
عالج السمنة
or obese patients should be encouraged to lose weight, and be considered for
bariatric surgery if appropriate. weight loss decreases the AHI and blood pressure, and
improves overall health and quality of life.
• In a minority, relief of nasal obstruction
• the avoidance of alcohol or sedating medication may prevent obstruction.
• Mandibular advancement devices that fit over the teeth and hold the mandible forward,
thus opening the pharynx, are an alternative that is effective in some patients. There is no
evidence that palatal surgery is of benefit.
• The gold standard therapy for the majority of patients is continuous positive airway pressure يثبت
(CPAP) delivered by a mask every night to splint the upper airway open. When CPAP is
tolerated, the effect is often dramatic , with relief of somnolence and improved daytime
performance, quality of life and survival. Unfortunately, 30%–50% of patients do not tolerate
CPAP or have poor adherence.
ۚمَن قَتَلَ نَفۡسَۢا بِغَيۡرِ نَفۡسٍ أَوۡ فَسَادٖ فِي ٱألَۡرۡضِ فَكَأَنَّمَا قَتَلَ ٱلنَّاسَ جَمِيعٗا وَمَنۡ أَحۡيَاهَا فَكَأَنَّمَآ أَحۡيَا ٱلنَّاسَ جَمِيعٗا